Advancements in Lipid Nanoparticle (LNP) Delivery Systems for mRNA Therapeutics

by

Overall, there has been a great enhancement in mRNA therapeutics in the last few years, mainly due to advancements in the pipelines of lipid nanoparticle (LNP) delivery systems. Currently, they find their application in delivering mRNA into the target cell for various therapeutic applications, right from vaccinations to gene editing vectors. This article focuses on the advances in mRNA delivery through LNP in the recent past, along with important points and their relevance to future treatments.

Introduction

Lipid nanoparticles, or LNPs, have greatly enhanced the delivery of nucleic acids, especially mRNA, because of their key characteristics of encapsulation and protection of the mRNA molecules and their delivery into cells. LNPs’ application in the creation of vaccines against COVID-19 has drawn attention to their usefulness in other spheres of treatment like oncology, genetic disorders, etc. It reviewed several developments in LNP technology in terms of their design, targeting, and clinical use.

Evolution of LNP Design

More design elements regarding LNPs have been introduced to improve their performance and targeting capabilities. Traditional LNPs consist of four main components: An ionizable lipid, a phospholipid, cholesterol, and a polyethylene glycol (PEG) lipid have been mentioned. Over the last few years, there have been works concerning enhancing these three components to facilitate the stability, delivery, and targeting of the LNPs.

One major advancement is the development of ionizable lipid nanoparticles that are selective for specific tissues. For instance, engineered ionizable LNPs are created for specific targeting of hepatocytes and liver sinusoidal endothelial cells. Depending on the particle size and the content of PEG-lipid, the researchers succeeded in delivering mRNA only to the given types. of cells and with fewer negative effects on the organism, improving the efficiency of the therapy.

Yearwise Publication Trend on “mrna therapeutics”

Find publication trends on relevant topics

Targeted Delivery and Specificity

One of the major issues remains delivering the mRNA to targeted cells or tissues at the specific target amount. Modern developments have been made in the ligand-locked and loaded method, in which LNPs possess ligands that make them reactive with receptors on the target cell. For instance, the attachment of mannose to the surface of LNPs has facilitated the delivery of RNA to LSECs but not to hepatocytes.

In cancer immunotherapy, LNPs have been applied for the delivery of mRNA-encoding tumor-specific antigens to dendritic cells to elicit a highly effective tumor-specific immune response. Lipid nanoparticles, particularly C1 lipid nanoparticles, which are a simplistic kind of nanovaccine, were proven to be highly effective in transporting mRNA to immune activators known as antigen-presenting cells and in activating T cells through a receptor known as TLR4. This system has been revealed to be beneficial in the prevention of tumors and cancer treatment.

Clinical Applications and Therapeutic Efficacy

Of all the categories of mRNA, the clinical success of lipid nanoparticle-mediated mRNA delivery has been all too well demonstrated by the COVID-19 vaccines, including the BNT162b2 vaccine by Pfizer-BioNTech and the mRNA-1273 vaccine by Moderna. Both of these vaccines utilize LNPs to carry mRNA that codes for the SARS-CoV-2 spike protein; they stimulate the immune system and help prevent the virus. This success has inspired attempts to extend the use of LNP technology to other disease indications.

In gene therapy, LNPs have been used as vectors for mRNA used for CRISPR-Cas9 gene editing. Another study proved that Cas9 mRNA and single-guide RNA (sgRNA) incorporated with LNPs provided liver targeting and Angptl3 gene editing. This approach was successful in lowering serum ANGPTL3 protein along with enhancing the lipid profiles in mice, which underlines the use of LSNE for targeting genetic diseases.

Besides, LNPs have been investigated for the delivery of mRNA-based vaccines against different infectious diseases and cancers. For example, the HA proteins of the H1N1 strain of the influenza A virus mRNA were encapsulated in cationic LNPs with protective immune responses in mice, as shown by the studies carried out. Some of these vaccines are capable of stimulating both humoral and cellular immunity, thus offering total coverage for viral diseases.

Safety and Immunogenicity

Stability and adjuvants are some of the key factors that must be evaluated in LNP-mediated mRNA therapeutics. In recent years, the use of LNP has applied modifications in the structure and core of LNP to minimize toxicity and reduce immune response. For example, the cationic lipids that integrate at the lipid head group and become uncharged at physiological pH have shown lesser inflammation than permanently charged lipids.

However, what has been observed to have some perspective is the use of non-inflammatory mRNA vaccines in autoimmune diseases. A translation investigation involving multiple sclerosis used a non-inflammatory mRNA vaccine approach, transecting mRNA to encode MS autoantigens in lymphoid dendritic cells. In this approach, regulatory T cells were induced to suppress autoreactivity without at the same time immunosuppressing the system; this is a form of therapeutic intervention in autoimmune diseases.

Recent Publications on “mrna therapeutics”

Find publications on relevant topics

Future Directions

Future progress for LNP-mediated mRNA therapeutics includes enhancement of targeting selectivity and delivery, as well as safety aspects. Nanotechnology and advances in bioengineering will allow for the creation of new LNPs to further deliver mRNA to various tissues and cells. Also, the use of mRNA in combination with other treatments, including small molecules and biologics, may improve the therapeutic effect.

A potential area of development is that of biodegradable lipid nanoparticles for mRNA delivery. These nanoparticles can be tailored with special features that let them break down in the body, making them less threatening to the body’s tissues after a short time. Also, the incorporation of targeting ligands, peptides, and antibodies increases the specificity of mRNA delivery to the target cells.

Conclusion

In general, the lipid nanoparticle delivery system is one of the most profound innovations that has opened up a broad range of opportunities in the application of mRNA-based therapeutics. In other cases, like vaccines, gene editing, or cancer immunotherapy, LNPs have indicated substantiated benefits as a delivery system. The advancement of this field has been advocated for, and this is because, as sure as the sun rises, one can expect more research and development for better therapeutic interventions, adding to the advancement of modern medicine.

References

  1. Qiu, M., Glass, Z., Chen, J., Haas, M., Jin, X., Zhao, X., Rui, X., Ye, Z., Li, Y., Zhang, F. and Xu, Q., 2021. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proceedings of the National Academy of Sciences, 118(10), p.e2020401118.
  2. Zhang, H., You, X., Wang, X., Cui, L., Wang, Z., Xu, F., Li, M., Yang, Z., Liu, J., Huang, P. and Kang, Y., 2021. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proceedings of the National Academy of Sciences, 118(6), p.e2005191118.
  3. Kim, M., Jeong, M., Hur, S., Cho, Y., Park, J., Jung, H., Seo, Y., Woo, H.A., Nam, K.T., Lee, K. and Lee, H., 2021. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Science advances, 7(9), p.eabf4398.
  4. Elia, U., Ramishetti, S., Rosenfeld, R., Dammes, N., Bar-Haim, E., Naidu, G.S., Makdasi, E., Yahalom-Ronen, Y., Tamir, H., Paran, N. and Cohen, O., 2021. Design of SARS-CoV-2 hFc-conjugated receptor-binding domain mRNA vaccine delivered via lipid nanoparticles. ACS nano, 15(6), pp.9627-9637.
  5. Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., Akilli-Öztürk, Ö., Kranz, L.M., Berger, H., Petschenka, J. and Diken, M., 2021. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science, 371(6525), pp.145-153.
  6. Riley, R.S., Kashyap, M.V., Billingsley, M.M., White, B., Alameh, M.G., Bose, S.K., Zoltick, P.W., Li, H., Zhang, R., Cheng, A.Y. and Weissman, D., 2021. Ionizable lipid nanoparticles for in utero mRNA delivery. Science advances, 7(3), p.eaba1028.
  7. Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B. and McGettigan, J., 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine, 384(5), pp.403-416.
  8. Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez Marc, G., Moreira, E.D., Zerbini, C. and Bailey, R., 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine, 383(27), pp.2603-2615.

Top Experts on “mrna therapeutics“